Fisher Wallace Laboratories has received Health Canada approval of the Fisher Wallace Stimulator medical device for the treatment of insomnia and chronic pain.
“Health Canada approval of the Fisher Wallace Stimulator medical device is a significant milestone for Fisher Wallace Laboratories and for insomnia and chronic pain patients across Canada,” says Charles Fisher, president of Fisher Wallace Laboratories, in a release. “It means that for many insomnia and chronic pain sufferers, relief is just 20 minutes away.”
The Fisher Wallace Stimulator is a portable, battery-powered medical device that delivers a gentle electrical current to the brain to stimulate neurotransmitters responsible for healthy sleep and pain suppression. The device is available without a prescription in Canada and patients can return it for a refund within 60 days of receipt if it does not relieve their symptoms.
Health Canada evaluated the safety and effectiveness of the Fisher Wallace Stimulator® based on data from multiple published studies involving hundreds of patients. Overall, published research and clinical practice indicate that the device has a 75% success rate in reducing or eliminating multiple forms of insomnia and chronic pain, according to the company. No adverse events occurred during any study involving the device and the device causes no serious side effects.
The Fisher Wallace Stimulator is also available in the United States, having been cleared for the treatment of insomnia, anxiety, depression, and chronic pain by the Food and Drug Administration in 1991.
